–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of ...
NEWPORT BEACH, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that Shanghai Fosun ...
“ Dermatologic Surgery ’s publication of this new clinical data demonstrating the efficacy of Xeomin ® (incobotulinumtoxinA) will prove critical in encouraging physicians to consider Xeomin ® ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Researchers found liquid-type botulinum ...
Please provide your email address to receive an email when new articles are posted on . New phase 2 results showed 40 units of Jeuveau sustained improvements in glabellar lines up to 6 months. Adverse ...
A randomized trial showed quantitative differences between four botulinum toxin A formulations among women treated for glabellar rhytids, with abobotulinum toxin A (ABoNT/A) and prabotulinum toxin A ...
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback